

Patterns and recent trends in mastectomy and breast conserving surgery for women with early-stage breast tumors in Missouri: An update and further investigation



CL Schmaltz, PhD^{1,2}; J Jackson-Thompson, MSPH, PhD^{1,2,3}; J Du, PhD^{1,4}; B Francis, MEd, CTR^{1,2}

- ¹ Missouri Cancer Registry and Research Center (MCR-ARC);
- ³ MU Informatics Institute, Columbia, Missouri;

- ² University of Missouri-Columbia (MU), School of Medicine, Dept. of Health Management & Informatics;
- ⁴ University of Missouri-Columbia (MU), College of Arts & Sciences, Dept. of Statistics

1. Background

- ❖ Most females age 18-64 diagnosed with an early-stage breast tumor in Missouri, 2008-2015, were surgically treated with either total (simple) mastectomy (TM), modified radical mastectomy (MRM), or breast conserving surgery (BCS).
- ❖ Last year, the Missouri Cancer Registry examined demographic differences between females receiving these treatments and noted a slight decrease in the % of cases getting BCS since 2008 with an increase in TM (& TM+MRM).

2. Purpose

❖ To continue monitoring trends in the surgical treatment of early-stage breast cancer in Missouri and describe the patterns by demographics & tumor characteristics.

3a. Methods: selection


- ❖ The "BCS" measure from the NCDB CP3R was adapted to central cancer registry data (consolidated records) along with corresponding measures for mastectomy.
 - Derived AJCC
 - * "RX Summ--Surg Prim Site" (item 1290) rather than the facility-specific "RX Hosp--Surg Prim Site" (item 670)
- Some conditions ignored:
 - Clinical vs pathological stage
 - Surgery "at this facility"
- Of those meeting eligibility selection & received surgical treatment:
 - Who received surgery other than BCS (codes 20–24)?
 - Different numerator criteria, categorized into:
 - ❖ Total mastectomy (codes 40-49, 75)
 - ❖ Modified Radical Mastectomy (codes 50–59, 63)
 - (other)
- ❖ Age <65 (since primary payer was of interest).</p>
- White & black only (due to small numbers for other races).

3b. Methods: analysis

- ❖ Logistic regression was used to analyze surgical trends among females with early-stage breast tumors (AJCC stage 0, I or II) while controlling for selected demographics.
- These surgical treatments were compared in terms of:
 - Survival (all-cause), controlling for selected demographics.
- Days between diagnosis & treatment.

4. Results

- * BCS more likely among (Odds ratio [95% CI]):
- Blacks vs whites:
 1.5 (1.3, 1.7)
- Earlier stages:
 - ❖ Stage 0 vs II:
 2.4 (2.2, 2.7)
 - ❖ Stage I vs II:
 2.4 (2.2, 2.5)
- ❖ PR+ tumors vs PR-(& borderline): 1.3 (1.2, 1.4)
- (ER status insig.)
- Private insurance vs Medicaid: 1.2 (1.1, 1.4)
- * Earlier years of diagnosis (see left plot below)
- Older females (see right plot below)



Logistic model also adjusted for geographical region & histologic group; Cox PH regression model also adjusted for geographical region, histologic group, & year of diagnosis.

5. Discussion

- These data provide quantitative population-based data on the surgical treatment for females diagnosed with earlystage breast tumors in Missouri.
- ❖ Trends and sociodemographic patterns may help inform patients & health professionals in Missouri by providing broad information on treatment options being utilized.

❖ Survival higher among (Hazard ratio [95% CI]):

(smaller hazard is better)

❖ BCS vs MRM: 0.75 (0.61, 0.93)
 ❖ (BCS vs TM & BCS vs TM+MRM had similar survival)

- Earlier stages:
 - Stage 0 vs II:
- 0.31 (0.23, 0.43)
- ❖ Stage I vs II:
 - 0.47 (0.39, 0.57)
- ER+/PR+ tumors (borderline grouped with negative):
 - ❖ ... vs ER+/PR−: 0.54 (0.42, 0.69)
 - ❖ ... vs ER−/PR+: 0.43 (0.25, 0.74)
- ❖ ... vs ER-/PR-: 0.44 (0.37, 0.53)
- Shorter time to surgery :
- HR for a 30-day decrease: 0.96 (0.92, 0.998)
- Females with private insurance:
 - ... vs uninsured:
 0.4 (0.26, 0.61)
 - ... vs Medicaid:
 0.4 (0.32, 0.49)
 - vs other insurance:
 0.36 (0.27, 0.47)
 - ... vs insured, no specifics: 0.58 (0.43, 0.77)
- Older females generally had higher survival (but survival was very high among all selected patients who have earlystage tumors).
- ❖ The treatment delay was shorter for patients receiving BCS than TM or MRM.

6. Contact

For more information about this project, contact:

Chester Lee Schmaltz, PhD

Senior Statistician,

MCR-ARC, Health Management & Informatics

SchmaltzC@Missouri.edu

573-882-7775, http://mcr.umh.edu

MCR-ARC core activities are supported in part by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Missouri Department of Health and Senior Services (DHSS) (5NU58DP003924-05 & NU58DP006299-01) and a Surveillance Contract between DHSS and the University of Missouri.

The authors would like to thank MCR-ARC Quality Assurance staff and the staff of facilities throughout Missouri and other states' central cancer registries for their dedication and desire for continuous quality improvement and submitting their reportable cases to MCR-ARC.

Revisions since presenting

- rev09, 2018-06-28:
 - Corrected the horizontal axes on the plots, had been mislabeled as 1, 2, 3,
- rev08:
 - Presented at the 2018 NAACCR conference in Pittsburgh, PA in June 2018.